C. diff. Annual H/C Conference Nov. 4-5

 

 

 

 

 

 

 9th Annual International C. diff.  Conference and Health EXPO: Live-Online, Two-Day Event

Dedicated to Healthcare Professionals Worldwide

November 4 – 5, 2021

Thursday, November 4th
Day 1 – Conference Opens at 10:00 a.m. EST
Day 1 – Day 1 – Concludes at 4:00 p.m. EST

Friday, November 5th
Day 2 – Conference Opens at 10:00 a.m. EST
Day 2 – Conference Concludes at 4:00 p.m. EST

 

 

 

 

Registration Is Complimentary This Year!

Please Note:  Keynote Speaker Dates and Time May Change ~ Please Check Back For Final Updates.  Thank You.

Welcome To the 9th Annual International C. diff.
Conference and Health EXPO

Conference Program Agenda

Stuart B. Johnson, MD, FIDSA, DTM&H
Conference Co-Chair & Keynote Speaker
Dr. Johnson, MD, FIDSA, DTM&H  Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus have involved the epidemiology pathogenesis and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic: TBA

Paul Feuerstadt, MD, FACG, AGAF
Conference Co-Chair & Keynote Speaker
Dr. Feuerstadt, MD, FACG, AGAF is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research, and graduated Summa Cum Laude. Following the completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency, Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital seeing outpatients in his offices in Hamden & Milford, CT
Presentation Topic: TBA

Professor Simon M. Cutting, Ph. D.
Professor Cutting, Ph. D., School of Biological Sciences at the Royal Holloway University of London  Professor Cutting is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus subtilis. After spending 7 years in the renowned laboratory of Professor Richard Losick at Harvard University Biological Laboratories (USA) he spent 3 years as an Assistant Professor at the University of Pennsylvania Medical School in Philadelphia. He returned to the UK in 1996 and since then has worked on developing bacterial spores as novel oral vaccines at the Royal Holloway, University of London.
Presentation Topic: TBA

Professor Martha Clokie, Ph. D.
Professor Clokie is a Professor of Microbiology at the University of Leicester.  Motivated by a desire to find cures for difficult-to-treat-diseases, Professor Clokie research is exploring the potential of using naturally occurring viruses, known as bacteriophages, to treat antibiotic-resistant infections. Bacteriophages are viruses that specifically infect bacteria and all bacteria have these naturally occurring enemies. Her work investigating alternative treatments for Clostridioides difficile (C. diff), a bacteria that can infect the bowel and cause diarrhea, has identified a large set of phages that effectively kill this pathogen. Working with an industrial partner, Enbiotix, this treatment is now being developed into a therapeutic.  Now, Professor Clokie is applying the same principles to look at other debilitating diseases.
Presentation Topic: TBA

Nicola Petrosillo, MD
Dr. Petrosillo earned a degree of  Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became a specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy. He is a fellow of the Pulmonary Vascular Research Institute and leader of the international task force for pulmonary hypertension associated with HIV, since 2007. He is a member of the Professional Affairs Subcommittee on Infectious Diseases and a member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is a Professor of Infectious Diseases at the Medical School of Specialization in Hygiene of the Tor Vergata University, Rome.
Presentation Topic: TBA

Barbara McGovern, MD
Dr. McGovern is VP, Medical Affairs of Seres. Dr. McGovern has over 25 years of experience in infectious diseases. Prior to joining Seres, she served as Medical Director in the Medical Affairs Division at AbbVie and helped to launch Viekera Pak for treatment of Hepatitis C virus (HCV) infection. At AbbVie, Dr. McGovern was a recipient of the 2015 President’s Award in recognition of the successful execution of 7 major publications in the New England Journal of MedicineLancet, and JAMA. As an academic clinician at Tufts Medical Center, she also authored more than 50 journal articles, editorials, and textbook chapters on HIV and HCV and was an Associate Editor of Clinical Infectious Diseases and a Deputy Editor at Up-To-Date.
Presentation Topic:  TBA

Florence Sejourne
Florence Séjourné is the Chief Executive Officer of DA VOLTERRA, a Paris-based biotech company that develops innovative products for the protection of the microbiota from antibiotic residues for which the medical need is increasing. Its most advanced product, DAV132, is a novel and unique oral phase 2 stage-product designed to fight the damaging effects of antibiotics on the large intestine. Prior to joining Da Volterra in 2008, Florence spent 11 years co-founding and developing Genfit (Euronext GNFT), now a leading public European biotech company in the field of metabolic and inflammatory diseases with a particular focus on liver and GI (NASH). Florence has thus the experience of successful entrepreneurial adventures and the capacity to set up and lead a highly professional organization from early research drug discovery to late-stage clinical development and market access.
Florence was trained in France (Mines Paritech, Biotechnology Major) and holds an MS in Pharmaceutics & Bioengineering from the University of Illinois at Chicago.
Presentation Topic: Update on the development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis.”

Karen Factor, MS. RD
Karen Factor, Registered Dietitian – uniquely trained in the science of nutrition and practice of dietetics to design and provide medical nutrition therapy  and other evidence-based applications of the Nutrition Care Process  that exemplify the profession’s systematic approach to providing high quality nutrition care.  Karen’s focus is on the prevention and management of diseases and to treat or rehabilitate an illness, injury, or condition, with the use of specific, indicated physical and cognitive nutrition care services comprised of one or more of the following aspects of the NCP: nutrition assessment/reassessment, nutrition diagnosis, nutrition intervention (e.g. nutrition counseling, therapeutic diet ordering, and nutrition education), nutrition monitoring, and evaluation, with a primary focus on gastrointestinal diseases and disorders.
Presentation Topic:  “From the Patient’s Voice Develops the Menu and No Two Are the Same.”

Tamas Haidegger, Ph. D.
Dr.  Haidegger received his MSc degrees from the Budapest University of Technology and Economics (BME) in Electrical Engineering and Biomedical Engineering, then Ph.D. in medical robotics. Currently, he is an associate professor at Óbuda University, serving as the director of the University Research and Innovation Center (EKIK), and as the technical lead of medical robotics research.
Presentation Topic: TBA

Zain Kassam, MD, MPH,
Dr. Kassam, Co-founder and  Chief Medical Officer of Finch Therapeutics. Before co-founding Finch, Dr. Kassam was the Chief Medical Officer of OpenBiome, whereas part of the founding team, he pioneered the application of the microbiome to treat disease. Dr. Kassam has served as a member of the Scientific Advisory Board of the American Gastroenterological Association Center for Gut Microbiome Research & Education and has authored over 150 peer-reviewed publications, abstracts, and book chapters related to the microbiome. Zain Kassam has an MD from Western University in Canada. He completed clinical training in Internal Medicine followed by a fellowship in Gastroenterology at McMaster University in Canada. He has an MPH from Harvard University in quantitative methods, and completed postdoctoral training in microbiome engineering at the Massachusetts Institute of Technology.
Presentation Topic:  TBA

Layla Ouldnouri
Layla Ouldnouri represents her team of
Junior Scientists.

Presentation Topic: “Bioluminescence of
C. difficile Spores”

 

Courtney Jones
Courtney Jones,  Associate Director, Marketing and Communications at Rebiotix, a Ferring Company.  Mrs. Jones specializes in the development and execution of global marketing and communications strategies, reputation building, and relationship management with Key Opinion Leaders in support of product development and corporate leadership within the biotechnology field. Responsible for strategic advances for the company’s novel microbiome-based technology platform into new therapeutic areas through targeted market research, supported by strong project management and expertise in the microbiome industry.
Presentation Topic: TBA

Professor Mark Wilcox, MD, FRCPath
Dr. Wilcox is the Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health, in England in the UK. He was Director of Infection Prevention, and Control, Doctor and Clinical Director of Pathology at LTHT. Dr. Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare-Associated Infection Committee and is a member of the HPA’s Program Board on Healthcare-Associated Infection & Antimicrobial Resistance. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents.
Presentation Topic:  TBA

Larry Kociolek, MD

Moderator – Group Discussion I
‘Recent Developments in Diagnosis, Treatment, and Prevention of C. difficile infection in Children.’

Dr. Kociolek, MD,  Attending Physician at the Ann & Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, the Medical Director of Infection Prevention and Control at Lurie Children’s whereby he coordinates the surveillance for and prevention of infection-related adverse events and leads administrative efforts to optimize patient and healthcare worker safety. Broadly, Dr. Kociolek’s academic interests are focused on healthcare epidemiology, particularly pediatric Clostridioides difficile infection and infections caused by antibiotic-resistant organisms.

Thomas J. Sandora, MD MPH

Panelist – Group Discussion I 

Dr. Sandora , MD, MPH is an Associate Professor of Pediatrics at Harvard Medical School and an attending in pediatric infectious diseases at Boston Children’s Hospital, where he has served as the Hospital Epidemiologist and Medical Director of Infection Prevention and Control since 2005. Dr. Sandora’s research interests focus on healthcare-associated infections in children, including epidemiology and prevention of pediatric    C. difficile infection. He is a co-author of the IDSA-SHEA Clinical Practice Guidelines for    C. difficile infection in adults and children, as well as the SHEA Compendium of strategies to prevent C. difficile infections in acute care hospitals.

Maribeth Nicholson, MD, MPH

Panelist – Group Discussion I 

Dr. Nicholson, MD, MPH, Assistant Professor of Pediatrics,  Associate Program Director, Pediatric Gastroenterology, Hepatology and Nutrition Fellowship Program.  Maribeth R. Nicholson, MD MPH, is an assistant professor of pediatric gastroenterology, hepatology and nutrition at Vanderbilt University Medical Center. a pediatrician, an epidemiologist. 

Sahil Khanna, MBBS, MS
Dr. Khanna, M.B.B.S., M.S.,  is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. His research and clinical interests include Epidemiology, Outcomes, and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations. He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program, and C. difficile related Clinical Trials at Mayo Clinic, Rochester, MN.
Presentation Topic: TBA

Sabine Hazan, MD
Dr. Hazan, M.D.,  has over 22 years of experience in clinical trials and is the Founder and CEO at both Ventura Clinical Trials and Malibu Specialty Center.  Dr. Hazan personally oversees clinical trials for high-profile studies on diseases such as Hepatitis C, Hypercholesterolemia, and Pancreatic Cancer.
Presentation Topic:  TBA

Ken Blount, Ph.D.
Dr. Blount, Ph. D. is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix,
Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a co-founder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a Ph.D. in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Presentation Topic: TBA

David Bischoff

David Bischoff is a C. diff. Survivor.  Dave will share his journey.

 

Presentation Topic: A C. diff. infection; A life-changing journey.

 

Friday, November 5, 2021
10:00 a.m. – 4:00 p.m. EST

         Welcome!

 

Curtis Donskey, MD
Dr. Donskey, MD, is an Infectious Disease physician at the Louis Stokes Cleveland VA Medical Center.  He has served as hospital epidemiologist and Chair of the Infection Control Committee since 1999.  His research focuses primarily on infection control of healthcare-associated pathogens, particularly Clostridioides difficile.  He has conducted numerous studies examining the role of the environment in the spread of pathogens and identifying effective cleaning methods.
Presentation Topic:  TBA

 

+ +

Doe Kley, RN, CIC, MPH, T-CHEST
Doe Kley, Senior Infection Preventionist for The Clorox Company joined as a member of the Clinical & Scientific Affairs Team in 2018. Doe is a registered nurse and is board certified in infection control & epidemiology. She holds a bachelor’s degree in microbiology and completed a master’s degree in public health at the University of Nevada. Doe has nearly 20 years of acute care infection prevention experience working in large healthcare systems such as Intermountain Healthcare in Utah and Kaiser Permanente in California. In her current role, she provides consultative services using her clinical expertise, input, and review of key materials to not only support marketing and sales, but also the development of practice tools for clinicians. Doe also engages with and provides thought leadership to external industry partners.
Presentation Topic: TBA

Kerrie Davies, Ph.D.
Dr. Davies, Ph. D., joined the University of Leeds as a Visiting Research Fellow in 2015. A researcher at Leeds Teaching Hospitals since 1998, and began Clinical Scientist training in 2004 becoming state registered in 2007, moving to Principal Clinical Scientist in 2016.  Principal Clinical Scientist for the Healthcare-Associated Infections Research Group Scientific lead COMBACTE-CDI, EUCLID, EUCLID 2, ORCHID, LUCID.  Clostridium difficile toxin detection methods and the UK Department of Health-funded multi-center study to determine the optimal methods for CDI diagnosis. This study changed the UK C. difficile laboratory diagnostic guidelines and has gone on to influence both the European (ESCMID) and US (SHEA) guidelines. Currently, I am a co-investigator and the scientific lead for work-packages 1 and 2 of COMBACTE-CDI, an Innovative Medicines Initiative (IMI2) Horizon2020 funded project to determine the burden of CDI across the whole of the healthcare economy in Europe.
Presentation Topic:  TBA

Kevin Garey, Pharm. D., M.S
Dr. Garey, Pharm.D., M.S., is Chair of the Department of Clinical Sciences and Administration and Professor of Pharmacy Practice at the University of Houston College of Pharmacy in Houston, Texas.  He also serves as Division Head, Experiential Therapeutics and Clinical Pharmacology. Additionally, he holds an academic appointment as Adjunct Associate Professor at the University of Texas School of Public Health in Houston.  Dr. Garey is an active member of the Society of Infectious Diseases Pharmacists and the American Society of Health-Systems Pharmacists (ASHP).  His research interests include antimicrobial stewardship activities to prevent and treat Clostridium difficile infection, surgical site infections, and systemic candidiasis.
Presentation Topic:  TBA

Erik Dubberke, MD, MSPH
Dr. Dubberke,  Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University.
Presentation Topic:  TBA

Kathy Bischoff, C. diff. Survivor
Kathy shares her journey……..” I am a C.diff. survivor. I am a wife, mother and my career was in Government. I retired excited to “live the good life.” My husband and I made plans to enjoy the beauty of the mountains, travel, and greet each day as a new adventure. Upon dismissal of an emergency hospital admission I was told “by the way, you have C.diff” and my life has forever changed.”

Dr. David Lyerly, Ph. D.
Dr. Lyerly, co-founder and Chief Science Officer of TECHLAB, Inc.  Dr. Lyerly received his B.S. from UNC-Chapel Hill and his Ph.D. in microbiology/Immunology from Wake Forest Bowman Gray School of Medicine. He and Dr. Tracy Wilkins founded TECHLAB in 1989. TECHLAB focuses on innovative diagnostic solutions for C. difficile, other enteric diseases, and intestinal inflammation.
Presentation Topic:  “A Four-pronged Threat: Clostridioides difficile Infection (CDI), Antibiotics, the Flu Season, and COVID-19.”

Maureen Spencer, RN, M.Ed. CIC
Maureen Spencer has been an Infection  Preventionist for over 40 years and is board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing an MRSA and Staph aureus Elimination Program at  New England Baptist Hospital, an Orthopedic Center of Excellence in  Boston. The groundbreaking work was published in the Journal of Bone and  Joint Surgery, Aug 2010.  In 2012 she was selected as one of the  “Who’s Who of Infection Prevention” and in 2017 she was recognized as a  Fellow of the Association for Professionals in Infection Control and  Epidemiology (FAPIC) for her advanced practice in infection prevention and leader within the field.   
Presentation Topic:  TBA

Paul Feuerstadt, MD, FACG, AGAF

Moderator – Group Discussion II

Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research, and graduated Summa Cum Laude. Following the completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency,

Stuart B. Johnson, MD, FIDSA, DTM&H

Panelist – Group Discussion II

Dr. Johnson, MD, FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus have involved the epidemiology pathogenesis and treatment of Clostridium difficile infection.

Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA

Panelist – Group Discussion II

Dr. Chopra, MD,MPH,FACP,FIDSA,FSHEA, an infectious disease specialist, Teena Chopra is a professor of internal medicine, infectious diseases, for the Wayne State University School of Medicine, as well as the corporate medical director of infection prevention and hospital epidemiology at the Detroit Medical Center. Chopra also serves on the Wayne State University Presidential Coronavirus Committee, assisting with preparations and response related to the virus.

Colleen Kelly, MD, FACG

Panelist – Group Discussion II

Dr. Kelly, MD, FACG,  focus of her research and clinical practice is fecal microbiota transplantation (FMT) for the treatment of C. difficile infection (CDI).  Dr. Kelly is currently one of the Principal Investigators for an NIH-funded FMT national registry which will answer important questions around real-world efficacy and safety of FMT and has assisted physicians and institutions around the country in developing FMT protocols. Dr. Kelly collaborates regionally, nationally and internationally with other physicians and scientists who have clinical and research interests in FMT.

Dave Powell, Ph.D.
Dr. Powell, Ph.D., is Chief Scientific Officer at Summit Therapeutics, where he leads the company’s scientific strategy across both Discovery and Development. This focuses on driving the innovative clinical research program supporting the ridinilazole Phase 3 studies for the treatment of Clostridioides difficile infection, as well as enabling pipeline sustainability through leadership of Summit’s preclinical discovery group.  David has over 25 years of experience in pharmaceutical drug discovery and development, he joined Summit in 2017 having served in a variety of leadership roles in GSK. His most recent role in GSK was as Director and Head of the Crick-GSK Biomedical LinkLabs where he led the collaboration between GSK and the Francis Crick Institute in London. David combines a wide array of biology expertise with a wealth of drug discovery experience across different therapeutic areas: Neurosciences, Cardiovascular, Immuno-Inflammation and Anti-Infectives.  David has a BSc and MSc from the National University of Ireland Galway, and a PhD from the University of Cardiff.
Presentation Topic: “Metagenomics Analysis of CoDIFy Phase 2 Samples Reveals Further Mechanistic Insights on the Efficacy of Ridinilazole”

Caterina Oneto, MD,  C. diff. Global Tele-Support Program, Co-Director      Dr.  Oneto is a Clinical Instructor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine.  Dr. Oneto is fluent in Spanish.  She graduated with a degree in Medicine and Surgery from the Universidad de Valparaiso in Chile and completed her residency in Internal Medicine at Cabrini Medical Center, where she served also as  Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. With expertise in endoscopy, colonoscopy, capsule endoscopy, liver, and pancreatic diseases,
Dr. Oneto’s special interests include IBD  (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of  Clostridioides difficile, and FMT (Fecal Microbiota Transplantation).
Presentation Topic:  TBA

Dale Gerding, MD, MACP, FIDSA, FSHEA
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. Before his present position,
Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA), and past chair of the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDS   
Presentation Topic:
   TBA

Glenn Tillotson, Ph.D.
Dr. Tillotson has over 30 years of experience in global infectious disease and with a focus in anti-infective drug development and medical education, and medical affairs. Demonstrated capabilities in broad-ranging educational initiatives aimed at improving patient health. Dr. Tillotson has published multiple publications and an e-book on C difficile. Recently he has been active in developing new products for Clostridioides difficile, MRSA, and MDR Gram-negative infections. Built and led a medical affairs team to prepare for the approval and launch of a fourth-generation macrolide for use in pneumonia. Most recently played a role in the approval of cefiderocol, a novel siderophore cephalosporin, in the USA. 
Presentation Topic:  “Antimicrobial stewardship and it’s impact on C difficile.”

Carlene Muto, MD, MS
Dr. Muto, MD. MS, Associate Professor of Medicine,  Medical Director of Infection Control and Hospital Epidemiology Medical Director for Infection Control Center for Quality Improvement and Innovation, UPMC Health System

Presentation Topic:  TBA

 

+ + + 

 

S P O N S O R S

We extend our gratitude to each sponsor who make this annual event possible.

To learn more about the Sponsors, please click on the graphics displayed below AND Visit http://www.cdiff2021.comfor more details.  Thank you.

 

Check Back For Keynote Speakers, On-Demand Poster Presentations, Sponsors, and Conference Updates!  www.cdiff2021.com

 

 

 

 

 

 

 

SAVE THE DATE FOR 2022